- Home
- CGC vs BWAY Comparison
CGC vs BWAY Comparison
Compare CGC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- BWAY
- Stock Information
- Founded
- CGC 2009
- BWAY 2003
- Country
- CGC Canada
- BWAY Israel
- Employees
- CGC N/A
- BWAY N/A
- Industry
- CGC Pharmaceuticals and Biotechnology
- BWAY Medical/Dental Instruments
- Sector
- CGC Health Care
- BWAY Health Care
- Exchange
- CGC Nasdaq
- BWAY Nasdaq
- Market Cap
- CGC 174.9M
- BWAY 207.4M
- IPO Year
- CGC N/A
- BWAY 2019
- Fundamental
- Price
- CGC $0.93
- BWAY $9.47
- Analyst Decision
- CGC Sell
- BWAY Strong Buy
- Analyst Count
- CGC 2
- BWAY 3
- Target Price
- CGC $2.00
- BWAY $13.17
- AVG Volume (30 Days)
- CGC 7.1M
- BWAY 54.4K
- Earning Date
- CGC 02-07-2025
- BWAY 03-11-2025
- Dividend Yield
- CGC N/A
- BWAY N/A
- EPS Growth
- CGC N/A
- BWAY N/A
- EPS
- CGC N/A
- BWAY 0.09
- Revenue
- CGC $192,343,833.00
- BWAY $41,016,000.00
- Revenue This Year
- CGC N/A
- BWAY $349.63
- Revenue Next Year
- CGC $2.50
- BWAY $27.16
- P/E Ratio
- CGC N/A
- BWAY $59.48
- Revenue Growth
- CGC N/A
- BWAY 29.04
- 52 Week Low
- CGC $0.88
- BWAY $4.61
- 52 Week High
- CGC $14.92
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- CGC 25.19
- BWAY 42.67
- Support Level
- CGC $1.09
- BWAY $9.36
- Resistance Level
- CGC $1.17
- BWAY $9.95
- Average True Range (ATR)
- CGC 0.09
- BWAY 0.44
- MACD
- CGC 0.02
- BWAY -0.04
- Stochastic Oscillator
- CGC 9.91
- BWAY 32.70
About CGC Canopy Growth Corporation
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.